Breaking the $50/g barrier in mAb manufacturing is now within reach 

For years, reducing monoclonal antibody (mAb) manufacturing costs below $50/g was viewed as a theoretical target. Yet, through the holistic application of process intensification across upstream processing, downstream processing, facility design, and digital operations, some innovative manufacturers are now demonstrating that mAb production costs can be reduced consistently below $50/g, and in some cases below $20/g.  

This progress has brought mAb manufacturing economics into sharp focus. High-profile initiatives, most notably the Gates Foundation’s aspirational target of $10/g for mAb production, aim to broaden global access, particularly in low- and middle-income countries.¹ Such targets highlight both the feasibility of further cost reduction and the growing urgency to close the remaining gap.

This blog post explores why the $50/g benchmark has become critical for commercial viability, why traditional cost-reduction strategies are reaching their practical limits, and how coordinated process intensification can help manufacturers break the barrier in practice.

Why $50/g matters now

Sustained demand growth, increasing molecular complexity, cost pressure, and sustainability requirements continue to reshape biopharmaceutical production. At the same time, biosimilar competition, margin compression, diversifying portfolios, and global demands for equitable drug access are making cost per gram a key limiting factor in biologics manufacturing.

Several shifts are changing the economics of mAb manufacturing:

• Average peak sales per molecule have declined while development costs have increased.  
• Pipelines are shifting toward biosimilars and more complex modalities, including multispecifics, antibody–drug conjugates, and Fc-fusion proteins.
• Demand profiles are changing, with more than 80% of commercial biologics requiring <500 kg/year and almost 50% requiring <100 kg/year.

• Increased regionalization and sustainability pressures are pushing manufacturers toward leaner production models.

   

Together, these trends fundamentally challenge the economics of traditional large-scale batch manufacturing and favor smaller, more agile, and more productive facilities enabled by intensified processing — shifting manufacturing strategies from scaling up to scaling out and scaling by time.

The limits of traditional cost reduction  

mAb manufacturing costs have fallen significantly over the past two decades. Improvements in cell-culture productivity, platform processes, and single-use technologies have helped reduce costs to below $100/g for large-demand production. However, traditional batch processes relying on Protein A-based purification have a practical limit of about $50/g.

Average upstream titers have increased from 0.5 – 1 g/L in the early 2000s to 5 – 10 g/L in 2026, with intensified processes exceeding 10 g/L. This improvement alone has reduced cost per gram by a factor of 2 – 5, but upstream gains alone are insufficient.

As upstream yields improve, downstream processing becomes the next challenge. Downstream operations typically account for about 50% of total mAb cost of goods, and chromatography alone contributes 25 – 30%, with Protein A chromatography representing the single largest cost contributor.  

Scaling up without intensification also creates risk. Large stainless-steel facilities require high capital investment, depend on high utilization, and can be vulnerable when demand is uncertain. Manufacturers need approaches that increase output per unit volume, footprint, and time rather than relying only on larger equipment.

Implementing process intensification

Process intensification has become a foundational strategy for the future of mAb manufacturing. It is not a single technology; it is a holistic framework aimed at maximizing productivity at the level of individual unit operations, processes, and facilities.

Process intensification involves the systematic increase of productivity per unit volume, time, and footprint through:

• Enhanced yields and mass transfer
• Reduced process residence times
• Parallelization of unit operations

• Continuous operation

   

Importantly, implementing these strategies does not require an all-or-nothing transition to fully continuous manufacturing. Process intensification can be adopted incrementally, from conventional batch processes to intensified batch operations, connected operations, and ultimately fully continuous manufacturing (Figure 1). This stepwise path allows manufacturers to capture cost benefits while building experience and confidence. Level 1 and Level 2 intensification strategies can already deliver significant gains, even before a facility reaches fully continuous operation.

When implemented with automation, real-time monitoring, and integrated control, intensified processes can reduce manufacturing costs to well below $50/g.

_{Figure 1:  A stepwise approach to process intensification 
Note – CoG = cost of goods, LBR = liter of bioreactor material, N = production-stage bioreactor} 

Breaking the $50/g barrier in practice

Breaking the $50/g barrier is not the result of one isolated process change. Instead, it requires a coordinated manufacturing strategy that combines single-use technologies, intensified upstream processing, downstream transformation, digital integration, and data-driven process development.

Each lever addresses a different constraint. Single-use technologies can reduce capital intensity and improve flexibility. Upstream intensification can increase productivity per unit volume. Downstream transformation can reduce cycle time, buffer use, chromatography costs, and facility footprint. Digital integration and data-driven co-development help connect those gains into a scalable manufacturing strategy.

Single-use technologies  

Single-use technologies are a foundational element of cost‑efficient intensified manufacturing. They reduce capital expenditure and facility construction timelines, eliminate clean-in-place and steam-in-place operations, reduce qualification requirements, and support modular, adaptable facilities sized for actual product demand.  

This is particularly relevant given that the majority of commercial mAbs are produced at annual volumes below 500 kg, where large stainless‑steel facilities suffer from large upfront capital investment, chronic underutilization, and changeover inefficiencies.

Upstream strategies

Intensified upstream strategies include high-titer intensified fed-batch, concentrated fed-batch, and high-productivity perfusion cell culture. These approaches increase volumetric productivity and allow smaller single-use bioreactors to achieve outputs comparable with much larger stainless-steel systems.

Downstream strategies

Downstream transformation is the dominant cost lever. Strategies include membrane-based rapid-cycling chromatography, multicolumn chromatography, continuous virus inactivation, and connected or continuous downstream workflows. These approaches can reduce resin and buffer volumes, shorten process time, minimize intermediate hold steps, and increase throughput.

Connected and continuous downstream processes can reduce timelines from five to six days to 24 – 48 hours by automating and parallelizing operations and reducing wait times. By eliminating overnight holds and enabling operations to run simultaneously, continuous downstream processing can substantially increase facility throughput while reducing cycle time, buffer use, and footprint.

Digital integration  

Digital integration is a critical enabler of process intensification. As processes become intensified and interconnected, manual operation becomes inefficient and unsustainable. Coordinated systems that support real-time monitoring, predictive and model-based control, synchronization of parallel unit operations, automated deviation detection, and electronic batch records help unlock the full value of intensified and continuous processes.

Data-driven co-development

Partnering with experienced technology and solution providers gives access to integrated platforms, digital infrastructure, and deep expertise. Collaborative use of data analytics, cost-modeling tools, and process simulations can help identify bottlenecks, predict intensification benefits, and demonstrate feasibility early in development — all of which are essential for delivering sustainable cost reductions.

Go deeper: Explore the full report and webinar

Breaking the $50/g barrier requires coordinated changes in upstream processing, downstream processing, single-use technologies, digital integration, and overall manufacturing strategy. The main limitation remains the traditional “Protein A + batch” approach, and moving beyond it is essential to delivering sustainable cost reductions without compromising quality or compliance.

For a deeper, data-driven view, download our custom report with BioProcess International. It examines scenario-based manufacturing economics, including greenfield and brownfield investments, production scale, facility utilization, and the impact of different process intensification strategies.

For a complementary perspective, watch the webinar on demand. The webinar offers a practical discussion with expert perspectives on how manufacturers can move from incremental optimization toward coordinated, end-to-end process intensification.

The $50/g benchmark is no longer just an ambition. It’s time to intensify.

References

_{1. Bill & Melinda Gates Foundation. Innovations for Exceptionally Low-Cost Monoclonal Antibody (mAb) Manufacturing [Grand Challenges]. https://gcgh.grandchallenges.org/challenge/innovations-exceptionally-low-cost-monoclonal-antibody-mab-manufacturing.}